{"id":2561,"date":"2018-02-22T17:57:09","date_gmt":"2018-02-22T12:27:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2561"},"modified":"2021-07-24T12:56:56","modified_gmt":"2021-07-24T07:26:56","slug":"snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","title":{"rendered":"Snippet: M&#038;A activities of big pharma\u2019s will fuel CAR-T cell therapy"},"content":{"rendered":"\n<p> <strong>Gilead Sciences Inc<\/strong>. bought <strong>Kite Pharma<\/strong> (USD 11.9 Billion) while <strong>Celgene<\/strong> took over <strong>Juno Therapeutics<\/strong> (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual <strong>CAR-T therapies<\/strong> will yield sales of <strong>USD 1 billion<\/strong>, the investing companies hope to rope in higher sales. With the death of five patients in the trials of Juno Therapeutics, <strong>Seattle Biotech <\/strong>now assumes its CAR-T cell therapy to be the best in class. While the equipment makers are now independent and are making their own inventions in <strong>CAR-T cell therapy<\/strong>, bigger companies are also getting involved in this business like GE Healthcare investing in cold chain experts etc. These advancements will bring in more deals for the development of cellular therapies and will further help the patients get better access to treatment with minimal side effects. However, there are few limitations to be taken into consideration such as cost-effectiveness and therapy limited to specific bloodlines. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies hope to rope in higher [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1118,1446,155,1155,204,1445,1333,1261,706],"industry":[17225],"therapeutic_areas":[],"class_list":["post-2561","post","type-post","status-publish","format-standard","hentry","category-snippets","tag-business-research","tag-car-t-therapies","tag-celgene","tag-consultancy","tag-delveinsight","tag-gilead-sciences-inc","tag-juno-therapeutics","tag-pharma-consulting","tag-pharmaceutical-industry","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>M&amp;A activities of big pharma\u2019s will fuel CAR-T cell therapy<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to boost their portfolio\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"M&amp;A activities of big pharma\u2019s will fuel CAR-T cell therapy\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to boost their portfolio\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-22T12:27:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:56+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"M&A activities of big pharma\u2019s will fuel CAR-T cell therapy","description":"Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to boost their portfolio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","og_locale":"en_US","og_type":"article","og_title":"M&A activities of big pharma\u2019s will fuel CAR-T cell therapy","og_description":"Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to boost their portfolio","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-22T12:27:09+00:00","article_modified_time":"2021-07-24T07:26:56+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","url":"https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy","name":"M&A activities of big pharma\u2019s will fuel CAR-T cell therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-02-22T12:27:09+00:00","dateModified":"2021-07-24T07:26:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to boost their portfolio","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-ma-activities-big-pharmas-will-fuel-car-t-cell-therapy"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CAR-T therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gilead Sciences Inc<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Juno Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">CAR-T therapies<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Gilead Sciences Inc<\/span>","<span class=\"advgb-post-tax-term\">Juno Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 22, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 22, 2018 5:57 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2561"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2561\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2561"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2561"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}